RISK FACTOR OF LYMPH NODE METASTASIS IN ENDOSCOPICALLY RESECTED T1 COLORECTAL CANCER

2019 ◽  
Author(s):  
GA Song ◽  
DH Baek ◽  
EY Park ◽  
JW Park ◽  
SH Lee
Keyword(s):  
Colorectal Cancer ◽  
Risk Factor ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Node Metastasis ◽  
T1 Colorectal Cancer

ID: 3521050 HOW TO DIAGNOSE TUMOR DIFFERENTIATION AS A RISK FACTOR FOR LYMPH NODE METASTASIS IN T1 COLORECTAL CANCER?

2021 ◽  
Vol 93 (6) ◽  
pp. AB99-AB100
Author(s):  
Katsuro Ichimasa ◽  
Shinei Kudo ◽  
Hideyuki Miyachi ◽  
Yuta Kouyama ◽  
Shingo Matsudaira ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factor ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Differentiation ◽  
Node Metastasis ◽  
T1 Colorectal Cancer

Tumor Budding and Pathological Differentiation Are Predictive Markers for Lymph Node Metastasis in T1 Colorectal Cancer

2006 ◽  
Vol 63 (5) ◽  
pp. AB216 ◽  
Author(s):  
Hitoshi Yamauchi ◽  
Kazutomo Togashi ◽  
Hiroshi Kawamura ◽  
Junichi Sasaki ◽  
Masaki Okada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Predictive Markers ◽  
Tumor Budding ◽  
Node Metastasis ◽  
Pathological Differentiation ◽  
T1 Colorectal Cancer

scholarly journals Tumour–stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: A multi-centre case-cohort study

2020 ◽  
pp. 205064062097532
Author(s):  
Hao Dang ◽  
Gabi W van Pelt ◽  
Krijn JC Haasnoot ◽  
Yara Backes ◽  
Sjoerd G Elias ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Prognostic Value ◽  
Adverse Outcome ◽  
Advanced Stage ◽  
Tumour Stroma ◽  
Node Metastasis ◽  
Increased Risk ◽  
T1 Colorectal Cancer

Background Current risk stratification models for early invasive (T1) colorectal cancer are not able to discriminate accurately between prognostic favourable and unfavourable tumours, resulting in over-treatment of a large (>80%) proportion of T1 colorectal cancer patients. The tumour–stroma ratio (TSR), which is a measure for the relative amount of desmoplastic tumour stroma, is reported to be a strong independent prognostic factor in advanced-stage colorectal cancer, with a high stromal content being associated with worse prognosis and survival. We aimed to investigate whether the TSR predicts clinical outcome in patients with non-pedunculated T1 colorectal cancer. Methods Hematoxylin and eosin (H&E)-stained tumour tissue slides from a retrospective multi-centre case cohort of patients with non-pedunculated surgically treated T1 colorectal cancer were assessed for TSR by two independent observers who were blinded for clinical outcomes. The primary end point was adverse outcome, which was defined as the presence of lymph node metastasis in the resection specimen or colorectal cancer recurrence during follow-up. Results All 261 patients in the case cohort had H&E slides available for TSR scoring. Of these, 183 were scored as stroma-low, and 78 were scored as stroma-high. There was moderate inter-observer agreement (κ = 0.42). In total, 41 patients had lymph node metastasis, 17 patients had recurrent cancer and five had both. Stroma-high tumours were not associated with an increased risk for an adverse outcome (adjusted hazard ratio = 0.66, 95% confidence interval 0.37–1.18; p = 0.163). Conclusions Our study emphasises that existing prognosticators may not be simply extrapolated to T1 colorectal cancers, even though their prognostic value has been widely validated in more advanced-stage tumours.

Deep Learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer

2021 ◽  
Author(s):  
Scarlet Brockmoeller ◽  
Amelie Echle ◽  
Narmin Ghaffari Laleh ◽  
Susanne Eiholm ◽  
Marie Louise Malmstrøm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factor ◽  
Deep Learning ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Early Colorectal Cancer ◽  
Node Metastasis

Does Additional Laparoscopic-Assisted Surgery after Endoscopic Submucosal Dissection Affect Short Outcomes in Patients with Stage T1 Colorectal Cancer? A Propensity Score-Based Analysis

2021 ◽  
pp. 1-7
Author(s):  
Pu Cheng ◽  
Zhao Lu ◽  
Fei Huang ◽  
Mingguang Zhang ◽  
Haipeng Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Endoscopic Submucosal Dissection ◽  
Hospital Stay ◽  
Node Metastasis ◽  
Submucosal Dissection ◽  
Additional Surgery ◽  
T1 Colorectal Cancer ◽  
Laparoscopic Assisted

<b><i>Background:</i></b> Additional surgery is necessary in cases with non-curative endoscopic submucosal dissection. It is still unknown whether preceding endoscopic submucosal dissection (ESD) for T1 colorectal carcinoma affects the short outcomes of patients who underwent additional surgery or not as compared with surgery alone without ESD. <b><i>Methods:</i></b> Patients (101 pairs) with T1 colorectal cancer who underwent additional laparoscopic-assisted surgery after endoscopic submucosal dissection (additional surgery group, <i>n</i> = 101) or laparoscopic-assisted surgery alone (surgery alone group, <i>n</i> = 101) were matched (1:1). Short-term morbidity, operation outcomes, and lymph node metastasis of the resected specimen were compared. <b><i>Results:</i></b> There were no significant differences between the additional laparoscopic-assisted surgery and laparoscopic-assisted surgery alone groups in lymph node metastasis (9.9 vs. 5.9%, respectively, <i>p</i> = 0.297), operative time (147.76 ± 52.00 min vs. 156.50 ± 54.28 min, <i>p</i> = 0.205), first flatus time (3.56 ± 1.10 days vs. 3.63 ± 1.05 days, <i>p</i> = 0.282), first stool time (4.30 ± 1.04 days vs. 4.39 ± 1.22 days, <i>p</i> = 0.293), time to intake (5.00 ± 1.18 days vs. 5.25 ± 1.39 days, <i>p</i> = 0.079), blood loss (44.75 ± 45.40 mL vs. 60.40 ± 78.98 mL, <i>p</i> = 0.603), harvest lymph nodes (18.74 ± 7.22 vs. 20.32 ± 9.69, <i>p</i> = 0.438), postoperative surgical complications (<i>p</i> = 0.733), and postoperative length of hospital stay (8.68 ± 4.00 days vs. 8.39 ± 1.94 days, <i>p</i> = 0.401). <b><i>Conclusion:</i></b> ESD did not increase the difficulty of additional laparoscopic-assisted surgery, hospital stay, or the incidence of postoperative complications. Additional laparoscopic-assisted surgery is safe and recommended for patients with T1 cancer at high risk of lymph node metastasis and residual cancer after non-curative ESD.

Sign in / Sign up

Export Citation Format

Share Document